Heart Failure

A recent publication from the HFSA highlights obesity, chronic kidney disease, diabetes mellitus, and hypertension as major driving forces.

A compiled list of the 8 most exciting presentations scheduled for the Heart Failure Society of American Annual Scientific Meeting 2025.

In a study, the prevalence of transthyretin cardiac amyloidosis reached 17% in Black men over 75 years old.

AKINESIS study finds kidney tubule biomarker IGFBP‑7 predicts 1-year death and heart failure readmission in acute heart failure patients.

Parent company CeleCor Therapeutics announced positive safety and efficacy endpoint data for their investigative GPIIb/IIIa inhibitor versus placebo.

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

When compared to transitions of care coordinators, MIH saw no additional benefit to either health status or 30-day hospital readmissions for postacute patients with HF.

The US Food and Drug Administration has approved bumetanide nasal spray for the treatment of edema in outpatient heart, liver, and kidney diseases.

Compared to standard devices, the first-of-its-kind AIRE-CHB model indicated incident CHB risk, outperforming standard ECG devices.

Life’s Essential 8 scores are substantially lower among adults aged ≥65 years who exhibit high blood pressure, stroke, or other cardiovascular diseases.

In the final segment of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 6 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 5 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 4 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 3 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 2 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

In part 1 of this 7-part HCPLive Special Report, experts discuss the recently released ASPC/HFSA heart failure prevention statement.

Semaglutide exhibited a 57% reduction in major adverse cardiovascular events compared to tirzepatide in patients with CVD with no prior history of diabetes.

Despite not lowering cardiovascular death or worsening heart failure, composite data did suggest the efficacy of in-hospital initiation of SGLT2 inhibitors.

A lower incidence of all-cause mortality and hospitalization for worsening heart failure proved digitoxin’s noninferiority in this phase 4 trial.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Cohosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Javed Butler, MD, to discuss the results of this major trial.

With positive topline phase 2 results, parent company Crinetics Pharmaceuticals, Inc., has announced plans to begin phase 3 testing in the second half of 2025.

Finerenone reduced diuretic needs while improving outcomes across various diuretic therapies.

Semaglutide 2.4 mg use was linked to lower medical costs and inpatient resource utilization among patients with overweight or obesity and heart failure.